NEW YORK (GenomeWeb News) – Prometheus Laboratories and Medco Research Institute today announced a deal to evaluate Prometheus' test for identifying patients who may benefit from a therapy for inflammatory bowel disease.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.